Why Testosterone Matters for Women: Hormone Therapy, Menopause, Libido, and Modern Women's Health

What Testosterone Actually Does in a Woman's Body

Testosterone is not a male hormone that women happen to have in small amounts. It is a core female androgen, produced in the ovaries, adrenal glands, and peripheral fat tissue, and it acts on receptors throughout the brain, bone, muscle, skin, cardiovascular system, and genitourinary tract. In healthy premenopausal women, serum testosterone averages between 15 and 70 ng/dL, depending on the assay, the laboratory, and the phase of the menstrual cycle.

Estrogen gets most of the clinical attention, but testosterone is actually the most abundant sex steroid in women by concentration across the lifespan. The ovaries produce roughly 25% of circulating testosterone directly, the adrenal glands contribute another 25%, and the remaining 50% is converted from androgen precursors, primarily androstenedione and DHEA, in peripheral tissues including fat, skin, and muscle.

How the Menstrual Cycle Affects Testosterone Levels

Testosterone is not static across your cycle. Levels peak around ovulation, which may contribute to the mid-cycle increase in sexual desire that many women notice. In the luteal phase, levels dip slightly. This fluctuation is clinically relevant: testing testosterone in the wrong cycle phase can give a misleading result. Most clinicians recommend drawing androgen levels in the early follicular phase, days 2 through 5, to get a consistent baseline.

What Testosterone Does at the Tissue Level

At the cellular level, testosterone binds to androgen receptors and also converts locally to estradiol via the enzyme aromatase. This dual action means its effects on bone and brain are mediated partly through androgenic pathways and partly through local estrogen production. Androgen receptors are present in the clitoris, vaginal wall, vulvar skin, and breast tissue, explaining why testosterone deficiency contributes to genitourinary symptoms that don't fully respond to estrogen therapy alone.

How Testosterone Levels Change Across a Woman's Life

Levels rise sharply during puberty, reach a broad peak in the early to mid-20s, and then decline gradually across the reproductive years. By the time a woman reaches natural menopause, her testosterone levels are already roughly 50% of peak values. The drop is gradual, unlike the sharp estrogen cliff at menopause.

Reproductive Years

During fertile years, testosterone supports sexual desire, clitoral sensitivity, bone mineral density maintenance, and lean muscle mass. Disruptions during this stage are most often caused by oral contraceptive pills, which raise sex hormone-binding globulin (SHBG) and dramatically lower free testosterone. A study published in the Journal of Sexual Medicine found that combined oral contraceptives raised SHBG by up to 400% and reduced free testosterone accordingly, an effect that can persist for months after stopping the pill.

Perimenopause

In perimenopause, the years before the final menstrual period, estrogen fluctuates widely while testosterone continues its slower age-related slide. Many women in this stage report reduced sexual desire, fatigue, and difficulty maintaining muscle mass, symptoms that estrogen therapy alone may not fully address. The clinical evidence base for testosterone therapy specifically in perimenopausal women is thinner than in postmenopausal women. More on that evidence gap in the treatment section below.

Postmenopause

After the final menstrual period, ovarian testosterone production continues at a reduced rate because the postmenopausal ovary still secretes androgens, primarily testosterone and androstenedione, in response to elevated LH. This is one reason oophorectomy has more dramatic androgen consequences than natural menopause.

Surgical Menopause

Bilateral oophorectomy removes the primary ovarian source of testosterone. Levels can fall by up to 50% within 24 to 48 hours of surgery. Women who undergo oophorectomy before natural menopause, for cancer risk reduction, endometriosis, or ovarian torsion, face a sharper and earlier testosterone decline than women who go through natural menopause. Standard hormone therapy after oophorectomy typically replaces estrogen and progesterone but does not address the androgen deficit.

Testosterone and Libido: What the Evidence Shows

Hypoactive sexual desire disorder (HSDD) is the most studied indication for testosterone therapy in women. HSDD is defined as persistent, bothersome low sexual desire not explained by relationship problems, medications, or another medical condition. It affects an estimated 10-15% of women of reproductive age and up to 32-40% of postmenopausal women.

The APHRODITE and INTIMATE Trials

The most cited evidence base comes from the randomized controlled trials of the transdermal testosterone patch Intrinsa, which was approved in Europe but rejected by the FDA in 2004 due to long-term cardiovascular and breast safety concerns at the population level. The APHRODITE trial enrolled 814 naturally postmenopausal women with HSDD and found that 300 mcg/day transdermal testosterone increased satisfying sexual events by approximately 74% compared with 59% on placebo over 52 weeks. The absolute difference was modest but statistically significant and, more relevant to clinical practice, meaningful to participants.

The Global Consensus Position Statement

In 2019, a joint position statement from The Menopause Society (then NAMS), the British Menopause Society, and 10 other international societies concluded that testosterone therapy is recommended for postmenopausal women with HSDD, that no currently available formulation in the US is specifically approved for women, and that clinicians should use male-formulated products at one-tenth the dose used in men. The statement explicitly noted that evidence in premenopausal women is insufficient to make a recommendation.

What "Off-Label" Actually Means in This Context

Off-label testosterone prescribing for women is legal, common, and done by gynecologists, menopause specialists, and reproductive endocrinologists across the United States. The absence of an FDA-approved female formulation is not a safety determination. It reflects a market and regulatory gap, not evidence that the therapy is harmful. Women deserve to understand that distinction.

Testosterone and Other Female Health Conditions

PCOS: Testosterone Is the Problem, Not the Treatment

In polycystic ovary syndrome, the androgen picture is reversed. Between 60-80% of women with PCOS have biochemical hyperandrogenism, meaning elevated testosterone, DHEA-S, or androstenedione. Elevated androgens drive acne, hirsutism, scalp hair thinning, and ovulatory dysfunction. Treatment in PCOS focuses on reducing androgen activity with combined oral contraceptives, spironolactone, or lifestyle changes that reduce insulin resistance and therefore lower androgen production.

Women with PCOS should not be prescribed additional testosterone. If you have PCOS and are experiencing low libido, the driver is more likely insulin resistance, depression, relationship factors, or the androgenic side effects of the condition itself rather than androgen deficiency.

Bone Health and Osteoporosis

Testosterone contributes to bone mineral density through both direct androgen receptor stimulation and local aromatization to estradiol within bone tissue. A prospective study of 2,449 women in the Study of Women's Health Across the Nation (SWAN) found that lower testosterone levels were associated with lower bone mineral density at the spine and hip, independent of estradiol. Women who undergo oophorectomy before 45 face both estrogen and androgen loss simultaneously, placing them at higher risk for accelerated bone loss if neither is replaced.

Female Pattern Hair Loss

Female pattern hair loss (androgenetic alopecia) in women is complex. Despite the name, it does not always correlate with elevated circulating androgens. The key factor is follicular sensitivity to dihydrotestosterone (DHT), the potent androgen derived from testosterone by 5-alpha reductase. A woman can have entirely normal testosterone levels and still experience androgen-driven hair thinning if her scalp follicles are particularly DHT-sensitive. Conversely, testosterone therapy does not universally worsen hair loss, though monitoring is prudent.

Mood, Cognition, and Energy

Androgen receptors are widely distributed in the brain, including regions involved in mood regulation, motivation, and executive function. Women with surgically induced menopause frequently report cognitive fog, low motivation, and depressive symptoms that persist on estrogen therapy alone. A Cochrane review found insufficient evidence to recommend testosterone specifically for mood and cognitive outcomes in menopausal women, but the biological plausibility is strong and individual clinical response is real. This is an area where the evidence gap is genuine, and any clinician who tells you otherwise is overstating the data.

Cardiovascular Health

The cardiovascular data in women is genuinely uncertain. High testosterone in premenopausal women, as seen in PCOS, is associated with adverse lipid profiles and increased cardiovascular risk. Whether physiological testosterone replacement in postmenopausal women carries the same risk is not established. The 2019 global consensus statement found no evidence of harm at physiological doses in short-to-medium-term trials, but long-term cardiovascular data in women specifically is limited. The FDA's 2004 rejection of Intrinsa cited concerns about long-term cardiovascular and breast safety data gaps, not demonstrated harm.

Pregnancy, Lactation, and Contraception: What You Must Know

Testosterone is contraindicated in pregnancy. Full stop.

Exogenous testosterone is a known teratogen in female fetuses. Prenatal androgen exposure causes virilization of female external genitalia, a condition analogous to congenital adrenal hyperplasia. Animal data and case reports of accidental exposure consistently show androgenic effects on fetal development. There is no safe dose established for human pregnancy.

Contraception Requirement

Any woman of reproductive potential who is prescribed testosterone therapy must use reliable contraception. Testosterone is not a contraceptive and does not reliably suppress ovulation. Progestin-only methods (the hormonal IUD, the implant, the shot) are generally preferred because they avoid the SHBG-raising effect of combined oral contraceptives, which would reduce the free testosterone you are trying to supplement.

If you are trying to conceive, testosterone therapy must be stopped before attempting pregnancy. Given the half-life of depot or gel formulations, a washout period of at least one to three menstrual cycles is recommended before conception attempts, though no formal FDA guidance exists for female use.

Lactation

Data on testosterone transfer into breast milk in humans is sparse. Testosterone is lipophilic and would be expected to transfer into milk. Animal studies show testosterone passage into milk, and potential effects on a nursing infant's hormonal development are unknown. Testosterone therapy during breastfeeding is not recommended based on precautionary principles. If you are postpartum and experiencing low libido or androgen-related symptoms while nursing, discuss non-hormonal approaches with your clinician first.

Diagnosing Low Testosterone in Women: The Testing Problem

This is an area where clinical practice is genuinely limited by technology. Standard immunoassay testosterone tests were designed and validated for male ranges. At female concentrations, their accuracy is poor. The Endocrine Society recommends liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the gold standard for measuring testosterone in women, but this assay is not available in most routine laboratory settings.

What this means practically: a lab report showing a testosterone level in the "normal female range" may or may not accurately reflect your true level. Symptoms matter as much as numbers. And a diagnosis of androgen deficiency in women is still not an officially recognized clinical entity in US guidelines, though clinicians use the concept routinely.

What to Ask Your Clinician

• Request LC-MS/MS testing, not standard immunoassay, if available
• Ask for free testosterone as well as total testosterone, since SHBG binding determines biological activity
• Test SHBG, DHEA-S, and prolactin at the same visit to rule out other causes of low desire
• If you are on combined oral contraceptives, understand that your free testosterone result reflects the pill's effect, not your baseline physiology

Testosterone Therapy Options for Women: What Is Actually Available

No testosterone product is FDA-approved for women in the United States. The products used are:

Transdermal Gels (Male Formulations, Female Doses)

Testosterone gel 1% (AndroGel) or 1.62% is prescribed at approximately one-tenth the male dose, typically 0.5-2 mg per day. Application sites used in women are the inner thigh or lower abdomen rather than the shoulder or upper arm, to reduce transfer risk to children and partners. Measuring such small volumes from male-formulated products introduces dosing imprecision.

Compounded Testosterone

Compounding pharmacies prepare testosterone creams, gels, and pellets specifically at female doses. The 2019 global consensus position statement cautioned that compounded pellets deliver supraphysiological testosterone levels in a significant proportion of women and are not recommended. Compounded topical preparations at physiological doses are a reasonable option when prescribed and monitored carefully.

Monitoring During Therapy

Total and free testosterone should be checked 4 to 6 weeks after starting therapy and then every 6 months. The 2019 consensus recommends targeting serum testosterone in the upper quartile of the normal female range, not exceeding the upper limit of normal. Signs of excess include acne, oily skin, hirsutism, clitoral enlargement, and voice deepening. If supraphysiological levels are detected, dose reduction or discontinuation is necessary.

Who This Is Right For, and Who It Is Not

Women Who May Benefit

• Postmenopausal women with confirmed HSDD who have not responded adequately to estrogen therapy and vaginal treatments
• Women post-oophorectomy with persistent low desire, fatigue, and reduced wellbeing on standard HRT
• Perimenopausal women with significant androgen-related symptoms, acknowledged with the caveat that evidence is thinner in this group

Women for Whom Testosterone Is Not Appropriate

• Women who are pregnant or trying to conceive (stop before attempting conception)
• Women who are breastfeeding
• Women with PCOS and confirmed biochemical hyperandrogenism
• Women with androgen-sensitive cancers, including certain breast cancer subtypes (discuss with your oncologist; the evidence here is evolving)
• Women with active acne, hirsutism, or voice changes suggesting existing androgen excess
• Women whose low libido is primarily driven by relationship conflict, depression, pelvic pain, or medication side effects rather than androgen deficiency

"The evidence supports testosterone use for postmenopausal HSDD at physiological doses, with appropriate monitoring. The mistake is treating every woman with low libido as androgen deficient without ruling out other contributors first," said Dr. Maya Okafor, WomanRx Medical Reviewer and board-certified OB-GYN.

What the Evidence Gap Means for You

Women have been systematically underrepresented in androgen research. Most of what is known about testosterone's effects comes from male studies extrapolated to female physiology, from PCOS research where androgens are pathologically elevated, and from a relatively small number of postmenopausal HSDD trials. Premenopausal data is genuinely thin. The lack of an FDA-approved female formulation has discouraged pharmaceutical investment in this space.

This is not a reason to avoid considering therapy if you have real, bothersome symptoms. It is a reason to work with a clinician who specializes in women's hormonal health, to monitor carefully, and to set realistic expectations. The therapy can meaningfully improve sexual function and wellbeing in the right candidate. It is not a broad-spectrum energy pill, and its use outside the studied indications requires honest conversation about what is known and what is not.